Moody’s downgrades Senegal to Caa1 amid rising debt concerns
Investing.com - Barclays initiated coverage on Exelixis (NASDAQ:EXEL) with an Equalweight rating and a $40.00 price target on Wednesday. The company, currently trading at $39.14, shows strong financial health with a "GREAT" rating according to InvestingPro metrics, maintaining impressive profitability with a 96.59% gross margin.
The research firm expects cabozantinib, Exelixis’s main value driver, to continue growing at mid-single digits until its patent expiry in 2029. Barclays’ sales projections for cabozantinib are relatively in line with consensus estimates, approximately 0.8% below consensus for 2029. The company has demonstrated solid execution with 10.73% revenue growth over the last twelve months.
Barclays forecasts total revenue approximately 8% below consensus for 2029, primarily due to lower sales contribution expectations from Exelixis’s pipeline products. The firm notes potential downside risk to both their own and consensus assumptions based on cabozantinib’s current sales trajectory. InvestingPro analysis suggests the stock is currently undervalued, with 8 additional exclusive insights available to subscribers.
Zanzalintinib, Exelixis’s main pipeline product, represents a potential near-term upside in colorectal cancer and non-clear cell renal carcinoma treatments. However, Barclays views the competitive landscape in colorectal cancer as challenging for zanzalintinib to advance to earlier treatment lines.
The $40 price target assumes a net present value of approximately $28 per share for cabozantinib and approximately $5 per share for zanzalintinib.
In other recent news, Exelixis reported its second-quarter 2025 earnings, revealing Cabometyx sales of $520 million, which did not meet Wall Street’s expectations of $530 million. In response, RBC Capital lowered its price target for Exelixis to $45, while Truist Securities adjusted theirs to $49, both maintaining their respective ratings. Furthermore, H.C. Wainwright reduced its price target to $46 following Exelixis’s decision to halt the Phase 3 portion of the STELLAR-305 trial for zanzalintinib. Goldman Sachs initiated coverage of Exelixis with a Buy rating, setting a price target of $47, citing the potential of zanzalintinib to offset future revenue losses. In leadership changes, Exelixis announced the appointment of Dana T. Aftab, Ph.D., as Executive Vice President of Research and Development. The company also noted the departure of Amy C. Peterson, M.D., from her executive roles. These developments highlight ongoing strategic and financial adjustments within Exelixis.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.